Ceva Animal Health renews its shareholding structure with all its long-standing partners and opens its capital to Mérieux Institute and ARCHIMED to accelerate its growth.
LIBOURNE, France, March 31, 2025 /PRNewswire/ -- Ceva Animal Health (Ceva), the world's fifth-largest animal health company, announces the restructuring of its capital. All investors, whether "Friends of Ceva" or pure investors led by Temasek, have renewed their investment, demonstrating their confidence in the company's ability to continue its sustained growth.
Ceva's management, led by Dr. Marc Prikazsky, has reinforced its participation and still retains the majority of voting rights, reaffirming the company's commitment to remaining independent. It is supported by a core group of long-term investors, known as "Friends of Ceva" ensuring a stable and committed shareholding structure for the group's development.
With 7,000 employees, Ceva is a global leader in animal health, particularly in vaccination. Operating directly in 47 countries, the company delivers its products, services and equipment's worldwide to veterinarians, livestock professionals, and pet owners.
To support innovation in animal health, the Bettencourt-Meyers and Mérieux, have increased their stake through the investment holding Téthys Invest and Mérieux Institute that joined forces with investment fund Mérieux Equity Partners. Canadian pension investor PSP Investments, a long-term investor in Ceva, has also significantly increased its ownership in the group. Other companies participating in the "Friends of Ceva" include Sofiprotéol, the investment branch of the French group Avril, the Japanese company Mitsui & Co., as well as some local investment funds and the Klocke family.
The long-standing minority investors have renewed their commitment, demonstrating their confidence in Ceva's future. Leading this group of partners is the Singapore-based global investment firm Temasek, joined by French investors EMZ and Sagard, Asia-based HOPU Investments, and U.S.-based Continental Grain Company. This sixth funding round also welcomes the addition of the French investment fund ARCHIMED, led by veterinarian Dr. Denis Ribon. Specializing in the healthcare sector, ARCHIMED focuses on supporting companies in expanding internationally and accelerating their research programs.
Since its founding in 1999, Ceva has grown its revenue fourteenfold, reaching €1.77 billion last year. Driven by innovation and deeply committed to preventive medicine, Ceva was the first veterinary company to develop and commercialize a cutting-edge nucleotide vaccine and invest in gene therapy for companion animals. Aware of its responsibility in addressing major global challenges, Ceva is strongly committed to reducing its environmental impact and promoting the preservation of animal biodiversity.
"I am delighted to see that in this new round of financing, the management's participation, supported by the 'Friends of Ceva', is being strengthened alongside our historic financial investors and new entrants. Ceva plays a major role in animal health, particularly in the fight against emerging diseases, sometimes zoonotic, and in the treatment of chronic diseases affecting our loyal four-legged companions. At Ceva, we are convinced that we must continue to create bridges between different health sectors to protect the health of ecosystems and humans as well as global food security," said Dr. Marc Prikazsky, Chairman and CEO of Ceva Animal Health.
Ceva would like to thank its advisors, Lazard, Rothschild, Weil, and Callisto, and their teams for their support.
About Ceva Animal Health
Ceva Animal Health (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers.
With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: "Together, beyond animal health".
2024 turnover: €1.77 billion
Contact: Emilie Barrail, Head of external communication, emilie.barrail@ceva.com
View original content:https://www.prnewswire.com/apac/news-releases/ceva-animal-health-renews-its-shareholding-structure-with-all-its-long-standing-partners-and-opens-its-capital-to-merieux-institute-and-archimed-to-accelerate-its-growth-302414782.html
SOURCE Ceva Santé Animale
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
22 minutes ago
- Los Angeles Times
States sue to block the sale of genetic data collected by DNA testing company 23andMe
Dozens of states have filed a joint lawsuit against the bankrupt DNA-testing company 23andMe to block the company's sale of its customers' genetic data without explicit consent. The suit, filed this week in U.S. Bankruptcy Court in the Eastern District of Missouri, comes months after 23andMe began a court-supervised sale process of its assets. The South San Francisco-based venture was once valued at $6 billion and has collected DNA samples from more than 15 million customers. The company's bankruptcy has raised questions over privacy standards for genetic data, which experts say is uniquely sensitive, immutable and irreplaceable if stolen. Twenty-seven states and the District of Columbia filed the lawsuit, arguing that 23andMe customers have an inherent right to their own genetic information. 'This isn't just data — it's your DNA,' said Oregon Atty. Gen. Dan Rayfield in a statement. 'It's personal, permanent, and deeply private. People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest bidder.' 23andMe announced in May that it would be sold to New York-based drug maker Regeneron Pharmaceuticals, which had agreed to comply with 23andMe's existing privacy policy. However, a competing offer from nonprofit TTAM Research Institute led the bankruptcy judge to reopen the auction last week. TTAM is run by 23andMe co-founder Anne Wojcicki, who has made several failed attempts to take the company private. In a statement, a 23andMe spokesperson said the lawsuit's claims 'are without merit' and that the sale of genetic data does not violate privacy regulations. 'Customers will continue to have the same rights and protections in the hands of the winning bidder,' the spokesperson said. 23andMe customers have the right to delete their genetic information from the company's database at any time, as outlined in the Genetic Information Privacy Act and the California Consumer Privacy Act. During a testimony in Washington earlier this week, 23andMe interim Chief Executive Joseph Selsavage said that 1.9 million customers have requested their data be deleted since the company's bankruptcy filing in March. Sara Geoghegan, senior counsel at the Electronic Privacy Information Center, said that 23andMe's privacy policy was subject to change and not adequate to protect customers' data. In an interview in March, she stressed the sensitivity of genetic data. 'I would be very concerned if I had given a swab to 23andMe,' she said. 'There is little we can do to control what happens to it.'
Yahoo
28 minutes ago
- Yahoo
Space Firm Voyager Technologies Jumps 82% After Upsized IPO
(Bloomberg) -- Voyager Technologies Inc. shares ended their debut trading day up 82% after the company raised $383 million in an upsized US initial public offering. Trump's Military Parade Has Washington Bracing for Tanks and Weaponry Shuttered NY College Has Alumni Fighting Over Its Future NY Long Island Rail Service Resumes After Grand Central Fire NYC Renters Brace for Price Hikes After Broker-Fee Ban NYC Mayoral Candidates All Agree on Building More Housing. But Where? The Denver-based defense contractor's stock closed at $56.48 each on Wednesday, versus the IPO price of $31 apiece. The company sold more than 12.3 million shares, after having marketed 11 million shares for $26 to $29. The trading gives Voyager Technologies a market value of $3.2 billion based on the outstanding shares listed in its filings. Janus Henderson Investors and Wellington Management have indicated an interest in buying a total of $60 million of shares in aggregate, the filings show. Founded in 2019 and recently rebranded from Voyager Space, Voyager Technologies serves both government and commercial clients across sectors including national security, advanced technology and space infrastructure, according to the filings. Space Station Replacement Voyager has a $217.5 million development grant with NASA to design Starlab, the commercial space station planned to replace the International Space Station, which is set to be decommissioned in 2030. Voyager plans to operate Starlab through a joint venture with equity partners including Airbus SE, Mitsubishi Corp., MDA Space Ltd. and Palantir Technologies Inc. The recent hostilities between President Donald Trump and Elon Musk jolted the share prices of companies in the sector on the prospect that SpaceX's dominant position had become vulnerable, though Musk later expressed regret over the rift. In an interview on Bloomberg TV Wednesday, Voyager Chief Executive Officer Dylan Taylor credited SpaceX as a crucial player in the industry, and said that there are other firms that are also doing great things. The space sector is unique in that companies are looking to collaborate and cooperate, he said. 'Really, everyone is rooting for everyone else,' Taylor said. 'I mean that sincerely, because it's important we get replacements up there prior to the International Space Station being decommissioned.' Another firm with links to both Voyager and the government is Palantir. A joint venture partner on the Starlab project, it's also a Voyager share holder, the filing shows. Voyager issued 228,365 shares to the data analytics firm in April last year as payment for for services including developing a prototype to schedule payloads to the ISS. 'We are both headquartered in Denver, they are across the street from us, we are friendly,' Taylor said. 'They are great partners and we coordinate with them closely and we have several initiatives where they play an important role.' Almost 84% of Voyager's revenue in 2024 stemmed from contracts with the US government and its affiliates, according to its filings. Voyager reported a net loss of $26.9 million on revenue of $34.5 million in the three months ended March 31, compared with a net loss of $14.8 million on revenue of $30.2 million in the same quarter last year. Trump's proposed 'Golden Dome' defense system, using space-based interceptors to shield the US from missile threats, could further boost Voyager's prospects. 'If the President gets what he wants for Golden Dome, that would potentially be a windfall,' Taylor said. Congressional Republicans are seeking $25 billion to start work on a project that Trump said could cost $175 billion overall. From the commercial space aspect of the business, even under a so-called skinny budget scenario, there would still be robust funding for commercial space stations, Taylor said. The offering was led by Morgan Stanley and JPMorgan Chase & Co. Its shares trade on the New York Stock Exchange under the symbol VOYG. --With assistance from Ed Ludlow and David Gura. (Updates with trading in first three paragraphs and CEO interview throughout.) New Grads Join Worst Entry-Level Job Market in Years The Spying Scandal Rocking the World of HR Software American Mid: Hampton Inn's Good-Enough Formula for World Domination The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Japan's JERA agrees to buy US LNG to rebalance supply portfolio
By Yuka Obayashi, Katya Golubkova and Kentaro Okasaka TOKYO (Reuters) -JERA, Japan's biggest power generator, has agreed to new supply deals for U.S. liquefied natural gas (LNG) from four projects to diversify its global portfolio away from its reliance on Australia, it said on Thursday. JERA plans to buy up to 5.5 million metric tons per annum (mtpa) of U.S. LNG under 20-year contracts, with deliveries starting around 2030. That total includes some previously reported deals as well as newly announced agreements. The move illustrates Japan's efforts to seek stable and flexible LNG supply to strengthen energy security and meet growing electricity demand driven by expanding data centres. The country is the world's second-largest LNG importer after China. JERA, Japan's biggest LNG buyer, has signed a heads of agreement with Sempra Infrastructure for 1.5 mtpa from its Port Arthur LNG phase 2 project and a HOA with Cheniere Marketing for up to 1 mtpa from Corpus Christi LNG and Sabine Pass LNG. The Japanese utility also signed a 20-year sales and purchase agreement (SPA) with U.S. LNG developer Commonwealth LNG for 1 mtpa from its Louisiana project. On Tuesday, sources familiar with the negotiations told Reuters about the deal though both companies declined to comment at the time. The 5.5 mtpa figure also includes its deal announced on May 29 with NextDecade to buy 2 mtpa from its Rio Grande LNG project. All four are 20-year, free-on-board contracts with no destination restrictions, although the Cheniere deal could go beyond 20 years, JERA said. "We made these decisions because cost-competitive and flexible LNG is essential as we look towards the 2030s," JERA's Global CEO and Chair Yukio Kani told Reuters. He added that LNG has become increasingly important amid rising power demand from data centres and the soaring costs of cleaner alternatives like hydrogen and ammonia. "We were also aiming to secure contracts with the projects already under development and tied to the EPC (engineering, procurement, and construction) agreements before the recent surge in LNG project costs and interest rates," he said. The announcement comes amid ongoing trade talks between Japan and the United States, though Kani stressed there was no government pressure behind the deals which he said were purely private sector decisions. "We are rebalancing towards the global supply mix," he said, to reduce its weighting toward Australia. After the new deals, the U.S. will supply nearly 30% of JERA's LNG mix, up from 10% now. Oceania and Asia, including Australia, currently account for more than half. JERA, jointly owned by Tokyo Electric Power and Chubu Electric Power, already buys U.S. supply from Freeport LNG and Cameron LNG. In 2023, it signed a 20-year contract to buy 1 mtpa from Venture Global's CP2 project. Sign in to access your portfolio
